Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
- First Posted Date
- 2005-05-23
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 912
- Registration Number
- NCT00111436
Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-05-23
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Amgen
- Registration Number
- NCT00111410
Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis
- First Posted Date
- 2005-05-18
- Last Posted Date
- 2008-08-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 150
- Registration Number
- NCT00111098
An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-05-18
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Amgen
- Registration Number
- NCT00111111
Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Phase 3
Completed
- Conditions
- CancerNon-Myeloid Malignancies
- Interventions
- First Posted Date
- 2005-05-18
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 718
- Registration Number
- NCT00111137
Enbrel® in Psoriatic Arthritis
Phase 4
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2005-05-18
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Amgen
- Registration Number
- NCT00111124
Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
Phase 2
Completed
- Conditions
- End Stage Renal Disease
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 850
- Registration Number
- NCT00110929
A Research Study for Patients With End-Stage Renal Disease (ESRD)
Phase 4
Completed
- Conditions
- End Stage Renal Disease
- Interventions
- Other: Standard of care
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2011-03-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 552
- Registration Number
- NCT00110890
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Phase 3
Completed
- Conditions
- AnemiaNon-Myeloid Malignancies
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 391
- Registration Number
- NCT00110955
Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00110981
© Copyright 2025. All Rights Reserved by MedPath